Medindia
Advertisement

Target of Potent Chronic Leukemia Drug Confirmed in New Study

by Kathy Jones on December 22, 2013 at 3:36 PM
Font : A-A+

 Target of Potent Chronic Leukemia Drug Confirmed in New Study

A molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia, according to a new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James).

In clinical trials, ibrutinib has often shown exceptional activity in people with chronic lymphocytic leukemia (CLL). The agent targets a molecule called Bruton's tyrosine kinase (BTK). It permanently incapacitates the molecule, and this stops the transmission of an important signal that promotes cell growth and proliferation. But ibrutinib also inhibits other molecules in CLL cells.

Advertisement

Like BTK, these molecules are proteins called kinases, and they might be important for CLL-cell survival, the researchers say. "Ibrutinib's lack of selectivity might mean that BTK is not the critical target in CLL, and that future drugs developed for CLL should focus on other molecules," says principal investigator Amy Johnson, PhD, associate professor of medicine in the division of hematology, and an OSUCCC - James researcher. However, the findings, published in the journal Blood, validated BTK inhibition. "This study shows that BTK is an important therapeutic target in CLL," says first author Jennifer Woyach, MD, assistant professor in the division of hematology and an OSUCCC - James researcher. "Inactivating BTK alone delayed CLL development in a mouse model, confirming that BTK is a clinically important target in CLL. This suggests that development of selective BTK inhibitors - in addition to multi-kinase inhibitors like ibrutinib - is reasonable in CLL." To investigate the role of BTK in CLL, Johnson, Woyach and their colleagues used CLL cells from patients and two CLL mouse models, one of which spontaneously develops a malignancy very similar to human CLL. The researchers blocked BTK activity two ways: genetically and pharmacologically, using ibrutinib.

Key findings included:
  • Inhibiting BTK expression in human CLL cells significantly decreased survival in tumor cells from 31 patients;
  • A mouse model with inactive BTK due to a point mutation survived significantly longer than mice with active BTK (18.3 versus 13.2 months, respectively);
  • In a mouse model of spontaneous CLL, animals treated with ibrutinib survived significantly longer than controls from the time of leukemia diagnosis (46 versus 24 days, respectively);
  • In the same mouse model, treatment with ibrutinib significantly delayed leukemia onset compared with controls (10.7 versus 7.0 months) and extended overall survival (14.5 versus 12.3 months, respectively).
"Overall," Johnson says, "our findings validate BTK as a target for CLL therapy and strongly suggest that selective kinase-inhibitors might work in CLL like the drug imatinib does in chronic myeloid leukemia."



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Gonorrhea
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Drug Toxicity Leukemia Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Signature Drug Toxicity Multiple Myeloma Bone Marrow Transplantation Hairy Cell Leukemia 

Recommended Reading
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess ......
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving ......
Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia (CLL) is one of the most common types of adult leukemia and is ......
Bone Marrow Transplantation
Preferred Term is Hematopoietic stem cell transplantation. In this stem cell from bone marrow are in...
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by ex...
Drug Toxicity
Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a d...
Hairy Cell Leukemia
Hairy cell leukemia (HCL) is a type of leukemia where there are increased numbers of abnormal B-lymp...
Multiple Myeloma
Multiple Myeloma caught public attention when model turned actress Lisa Ray, who worked in Deepa Meh...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use